Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16122816 | 0.92 | KRAS (0.45) | KRASGAAEGFRERBB2MAPT | |
| SCHEMBL16117729 | 0.92 | KRAS (0.47) | KRASGAAMEN1KMT2AEGFR | |
| SCHEMBL16117735 | 0.92 | KRAS (0.47) | KRASGAAMEN1KMT2AEGFR | |
| SCHEMBL16117750 | 0.92 | KRAS (0.50) | KRASGAAMEN1KMT2AEGFR | |
| SCHEMBL16122680 | 0.91 | KRAS (0.46) | KRASGAAEGFRKDM1AMAOA | |
| SCHEMBL16117760 | 0.90 | KRAS (0.50) | KRASGAAKMT2AEGFRKDM1A | |
| SCHEMBL16122793 | 0.89 | KRAS (0.44) | KRASGAAEGFRKDM1AMAOA | |
| SCHEMBL16122813 | 0.88 | KRAS (0.53) | KRASGAAMEN1KMT2AEGFR | |
| SCHEMBL16122760 | 0.88 | KRAS (0.53) | KRASGAAMEN1KMT2AEGFR | |
| SCHEMBL16122711 | 0.88 | KRAS (0.50) | KRASGAAMEN1KMT2AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885GAA 1747/4885MEN1 2271/4885 |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885GAA 1747/4885MEN1 2271/4885 |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885GAA 1747/4885MEN1 2271/4885 |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | KRAS, NRAS, HRAS | KRAS 1/4885GAA 1747/4885MEN1 2271/4885 |
| US-10273207-B2 | Covalent inhibitors of kras G12C | KRAS, NRAS, HRAS | KRAS 1/4885GAA 1747/4885MEN1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.